Ipratropium Bromide

Catalog No.S1683 Batch:S168301

Print

Technical Data

Formula

C20H30BrNO3

Molecular Weight 412.37 CAS No. 22254-24-6
Solubility (25°C)* In vitro DMSO 83 mg/mL (201.27 mM)
Water 83 mg/mL (201.27 mM)
Ethanol 83 mg/mL (201.27 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Ipratropium Bromide is an antagonist of M3 type muscarinic acetylcholine receptors, used for the treatment of chronic obstructive pulmonary disease (COPD).
Targets
mAChR [1]
In vitro Ipratropium bromide combined with Formoterol partially protects the lungs against the chronic inflammation and airspace enlargement by reducing neutrophilic infiltration possibly via the inhibition of MMP-9 activity. [1] Ipratropium bromide (1 nM) significantly increases [Ca(2+)](i), decreases forward scatter and increases annexin-V-binding. Ipratropium bromide treatment is followed by slight but significant increase of hemolysis. Ipratropium bromide triggers suicidal erythrocyte death or eryptosis, an effect mainly due to stimulation of Ca(2+)-entry. [2]
In vivo Ipratropium dry powder inhalation (DPI) at a dose of 2400 mg/horse is an effective bronchodilator in these horses at rest but it has little effect on the airway calibre during the recovery period. [3] Ipratropium significantly attenuates the lung lesions associated with parenchyma inflammatory cell influx and congestion observed in the cadmium treated rats. Ipratropium bromide partially protects the lungs against the inflammation by reducing neutrophilic infiltration. [4] Ipratropium is an antagonist for pre-junctional muscarinic inhibitory receptors on pulmonary parasympathetic nerves and also confirms its potent antagonist actions on post-junctional muscarinic receptors in the airway smooth muscle in the guinea-pig. [5] Ipratropium decreases the maximal change in pleural pressure during tidal breathing (delta Pplmax) and pulmonary resistance (RL) and increases dynamic compliance (Cdyn) in horse. [6]

Protocol (from reference)

Selleck's Ipratropium Bromide has been cited by 2 publications

Cholinergic neuron-like D-U87 cells promote polarization of allergic rhinitis T-helper 2 cells. [ Int Forum Allergy Rhinol, 2020, 10(2):233-242] PubMed: 31658507
Clusterwise Peak Detection and Filtering Based on Spatial Distribution To Efficiently Mine Mass Spectrometry Imaging Data. [ Anal Chem, 2019, 91(18):11888-11896] PubMed: 31403280

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.